Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, ...

Conduit Pharmaceuticals (CDT) announces that its board of directors has approved a 1-for-100 reverse stock split of the Company’s common stock.

Conduit Pharmaceuticals Inc. (NASDAQ:CDT), a clinical stage life science company with a current market capitalization of $7.49 million, announced that it will implement a 1-for-100 reverse stock split ...